[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

86 10 66887329

Email address



Type 2 Diabetes

Treatment type


Investigational product



Phase 3


Jiangsu HengRui Medicine Co., Ltd.

ClinicalTrials.gov identifier


Study number


Date first posted

October 18, 2013

Date last update

October 22, 2013

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the efficacy and safety of SP2086 as monotherapy in patients with Type 2 Diabetes Mellitus in Metformin monotherapy Who Have Inadequate Glycemic Control treated with diet and exercise for 3 months

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. Patients diagnosed with type 2 diabetes mellitus
  2. Patients have treated with diet/exercise at least 3 months
  3. 7.5% ≤HbA1C ≤11.0% at screening,7.0% ≤HbA1C ≤10.5% after run-in
Exclusion criteria
  1. Patient has history of type 1 diabetes mellitus
  2. Patient has history of ketoacidosis
  3. Patient has history of severe unconscious hypoglycemosis
  4. Patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis
  5. Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical
  6. Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg
  7. Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL);total bilirubin >2×UNL; creatinine>1.5 mg/dL (Male,132.6μmol/L) ,>1.4 mg/dL(Female,123.8μmol/L)
  8. Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery
  9. Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. )
  10. Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on
  11. Patient has history of malignancy
  12. Patient has history of alcohol or drug abuse

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site